Zai Lab Ltd

Zai Lab Limited is a biopharmaceutical company that discovers, develops, and commercializes products across oncology, immunology, neuroscience, and infectious diseases. The company maintains a portfolio of marketed drugs including Zejula (niraparib) for ovarian cancer, VYVGART (efgartigimod) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin infections, and Qinlock (ripretinib) for gastrointestinal stromal tumors. Additional approved products include Optune for glioblastoma multiforme, Xacduro (sulbactam-durlobactam) for hospital-acquired and ventilator-associated bacterial pneumonia, and Augtyro for ROS1-positive and ALK-positive non-small cell lung cancer.

The company's pipeline encompasses several development-stage candidates, including bemarituzumab, tisotumab vedotin, and repotrectinib in oncology, along with xanomeline and trospium chloride for neuroscience indications. Zai Lab operates through multiple licensing and collaboration agreements with major pharmaceutical companies including Amgen, Bristol-Myers Squibb, argenx, Pfizer, and others, leveraging external partnerships to support its product development strategy.

The company maintains operations with approximately 1,869 full-time employees and is headquartered in Pudong, China. Zai Lab was incorporated in the Cayman Islands in 2013 and is listed on Nasdaq.